Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.86
VIVO's Cash-to-Debt is ranked lower than
67% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.86 vs. VIVO: 0.86 )
Ranked among companies with meaningful Cash-to-Debt only.
VIVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 14.28 Max: No Debt
Current: 0.86
Equity-to-Asset 0.66
VIVO's Equity-to-Asset is ranked higher than
64% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. VIVO: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
VIVO' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.78 Max: 0.92
Current: 0.66
0.35
0.92
Interest Coverage 36.27
VIVO's Interest Coverage is ranked lower than
57% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.70 vs. VIVO: 36.27 )
Ranked among companies with meaningful Interest Coverage only.
VIVO' s Interest Coverage Range Over the Past 10 Years
Min: 36.27  Med: No Debt Max: No Debt
Current: 36.27
Piotroski F-Score: 4
Altman Z-Score: 6.27
Beneish M-Score: -3.25
WACC vs ROIC
6.57%
18.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 24.46
VIVO's Operating Margin % is ranked higher than
93% of the 166 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.66 vs. VIVO: 24.46 )
Ranked among companies with meaningful Operating Margin % only.
VIVO' s Operating Margin % Range Over the Past 10 Years
Min: 24.46  Med: 28.66 Max: 32.9
Current: 24.46
24.46
32.9
Net Margin % 15.13
VIVO's Net Margin % is ranked higher than
92% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.76 vs. VIVO: 15.13 )
Ranked among companies with meaningful Net Margin % only.
VIVO' s Net Margin % Range Over the Past 10 Years
Min: 15.13  Med: 18.98 Max: 22.09
Current: 15.13
15.13
22.09
ROE % 17.64
VIVO's ROE % is ranked higher than
84% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. VIVO: 17.64 )
Ranked among companies with meaningful ROE % only.
VIVO' s ROE % Range Over the Past 10 Years
Min: 17.64  Med: 22.86 Max: 25.78
Current: 17.64
17.64
25.78
ROA % 12.32
VIVO's ROA % is ranked higher than
90% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. VIVO: 12.32 )
Ranked among companies with meaningful ROA % only.
VIVO' s ROA % Range Over the Past 10 Years
Min: 12.32  Med: 20.4 Max: 22.5
Current: 12.32
12.32
22.5
ROC (Joel Greenblatt) % 53.31
VIVO's ROC (Joel Greenblatt) % is ranked higher than
82% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. VIVO: 53.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
VIVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.31  Med: 67.18 Max: 89.27
Current: 53.31
53.31
89.27
3-Year Revenue Growth Rate 0.90
VIVO's 3-Year Revenue Growth Rate is ranked lower than
59% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. VIVO: 0.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
VIVO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 9 Max: 19.7
Current: 0.9
0.9
19.7
3-Year EBITDA Growth Rate -3.00
VIVO's 3-Year EBITDA Growth Rate is ranked lower than
60% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. VIVO: -3.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
VIVO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -3  Med: 6.5 Max: 22.6
Current: -3
-3
22.6
3-Year EPS without NRI Growth Rate -5.80
VIVO's 3-Year EPS without NRI Growth Rate is ranked lower than
56% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. VIVO: -5.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
VIVO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.8  Med: 8.5 Max: 35.2
Current: -5.8
-5.8
35.2
GuruFocus has detected 3 Warning Signs with Meridian Bioscience Inc $VIVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VIVO's 10-Y Financials

Financials (Next Earnings Date: 2017-04-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VIVO Guru Trades in Q1 2016

Paul Tudor Jones 39,675 sh (+117.78%)
Joel Greenblatt 171,177 sh (+97.95%)
Jim Simons 1,710,600 sh (+8.64%)
Chuck Royce 48,300 sh (unchged)
Mario Gabelli 140,000 sh (unchged)
Keeley Asset Management Corp 89,275 sh (-7.12%)
» More
Q2 2016

VIVO Guru Trades in Q2 2016

Joel Greenblatt 264,250 sh (+54.37%)
Paul Tudor Jones 40,961 sh (+3.24%)
Jim Simons 1,761,076 sh (+2.95%)
Mario Gabelli 140,000 sh (unchged)
Chuck Royce 48,300 sh (unchged)
Keeley Asset Management Corp 82,375 sh (-7.73%)
» More
Q3 2016

VIVO Guru Trades in Q3 2016

Jim Simons 1,914,676 sh (+8.72%)
Chuck Royce 48,300 sh (unchged)
Keeley Asset Management Corp 82,375 sh (unchged)
Mario Gabelli 140,000 sh (unchged)
Joel Greenblatt 246,898 sh (-6.57%)
Paul Tudor Jones 27,903 sh (-31.88%)
» More
Q4 2016

VIVO Guru Trades in Q4 2016

Discovery Group I, LLC 340,282 sh (New)
Chuck Royce 116,928 sh (+142.09%)
Mario Gabelli 140,000 sh (unchged)
Keeley Asset Management Corp Sold Out
Jim Simons 1,873,200 sh (-2.17%)
Joel Greenblatt 211,281 sh (-14.43%)
Paul Tudor Jones 21,515 sh (-22.89%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 2835
Compare:NYSE:ARA, NAS:NRCIA, NAS:NEO, NAS:NTRA, NAS:HSKA, NAS:LNTH, NAS:NVDQ, NAS:QDEL, NYSE:NVTA, NAS:BEAT, NAS:OXFD, NYSE:ENZ, NAS:ONVO, NAS:SRDX, NAS:RDNT, NAS:MGEN, NAS:ALOG, NAS:FLGT, NAS:QTNT, OTCPK:CBIS » details
Traded in other countries:MR4.Germany,
Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases.

Meridian Bioscience Inc was incorporated in Ohio in 1976. The Company is an integrated life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers; and the contract development and manufacture of proteins and other biologicals under cGMP conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. Its segments are Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations in Cincinnati, Ohio, and the sale and distribution of diagnostic test kits in the countries comprising North, Central and South America (the Americas); Europe, Middle East and Africa (EMEA); and other countries outside of the Americas and EMEA (rest of the world, or ROW). In the Diagnostics Segment, its testing platforms include: Isothermal DNA Amplification (illumigene brand); Rapid Immunoassay (TRU, ImmunoCard and ImmunoCard STAT! brands); and Enzyme-linked Immunoassay ( Premier brand). Its product portfolio includes over 140 diagnostic tests and transport media, and is marketed to acute care hospitals, reference laboratories and outpatient clinics in over 70 countries around the world. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia, and the sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bioresearch reagents domestically and abroad, including sales and business development offices in Singapore and Beijing, China. The Life Science segment also includes the contract development and manufacture of cGMP clinical grade proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines.

Ratios

vs
industry
vs
history
PE Ratio 18.51
VIVO's PE Ratio is ranked higher than
71% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.02 vs. VIVO: 18.51 )
Ranked among companies with meaningful PE Ratio only.
VIVO' s PE Ratio Range Over the Past 10 Years
Min: 18.07  Med: 26.21 Max: 48.49
Current: 18.51
18.07
48.49
Forward PE Ratio 17.06
VIVO's Forward PE Ratio is ranked higher than
61% of the 46 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.83 vs. VIVO: 17.06 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 18.51
VIVO's PE Ratio without NRI is ranked higher than
73% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.50 vs. VIVO: 18.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
VIVO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 18.07  Med: 26.21 Max: 48.28
Current: 18.51
18.07
48.28
Price-to-Owner-Earnings 18.57
VIVO's Price-to-Owner-Earnings is ranked higher than
75% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 27.06 vs. VIVO: 18.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
VIVO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.12  Med: 31.18 Max: 68.13
Current: 18.57
18.12
68.13
PB Ratio 3.29
VIVO's PB Ratio is ranked higher than
53% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.55 vs. VIVO: 3.29 )
Ranked among companies with meaningful PB Ratio only.
VIVO' s PB Ratio Range Over the Past 10 Years
Min: 3.22  Med: 6.01 Max: 11.73
Current: 3.29
3.22
11.73
PS Ratio 2.81
VIVO's PS Ratio is ranked higher than
52% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. VIVO: 2.81 )
Ranked among companies with meaningful PS Ratio only.
VIVO' s PS Ratio Range Over the Past 10 Years
Min: 2.74  Med: 5.2 Max: 10.9
Current: 2.81
2.74
10.9
Price-to-Free-Cash-Flow 16.39
VIVO's Price-to-Free-Cash-Flow is ranked higher than
63% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.34 vs. VIVO: 16.39 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
VIVO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.01  Med: 30.14 Max: 70.85
Current: 16.39
16.01
70.85
Price-to-Operating-Cash-Flow 14.40
VIVO's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.21 vs. VIVO: 14.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
VIVO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.09  Med: 25.16 Max: 49.37
Current: 14.4
14.09
49.37
EV-to-EBIT 11.58
VIVO's EV-to-EBIT is ranked higher than
85% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.46 vs. VIVO: 11.58 )
Ranked among companies with meaningful EV-to-EBIT only.
VIVO' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.38  Med: 16.8 Max: 34.9
Current: 11.58
11.38
34.9
EV-to-EBITDA 10.02
VIVO's EV-to-EBITDA is ranked higher than
74% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.84 vs. VIVO: 10.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
VIVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.83  Med: 15.15 Max: 31.1
Current: 10.02
9.83
31.1
PEG Ratio 5.11
VIVO's PEG Ratio is ranked lower than
79% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. VIVO: 5.11 )
Ranked among companies with meaningful PEG Ratio only.
VIVO' s PEG Ratio Range Over the Past 10 Years
Min: 0.98  Med: 3.47 Max: 21.06
Current: 5.11
0.98
21.06
Shiller PE Ratio 15.78
VIVO's Shiller PE Ratio is ranked higher than
87% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.56 vs. VIVO: 15.78 )
Ranked among companies with meaningful Shiller PE Ratio only.
VIVO' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.43  Med: 34.53 Max: 134.75
Current: 15.78
15.43
134.75
Current Ratio 5.99
VIVO's Current Ratio is ranked higher than
86% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. VIVO: 5.99 )
Ranked among companies with meaningful Current Ratio only.
VIVO' s Current Ratio Range Over the Past 10 Years
Min: 1.85  Med: 5.5 Max: 10.21
Current: 5.99
1.85
10.21
Quick Ratio 3.87
VIVO's Quick Ratio is ranked higher than
73% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. VIVO: 3.87 )
Ranked among companies with meaningful Quick Ratio only.
VIVO' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 3.66 Max: 8.77
Current: 3.87
1.06
8.77
Days Inventory 222.81
VIVO's Days Inventory is ranked lower than
92% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.88 vs. VIVO: 222.81 )
Ranked among companies with meaningful Days Inventory only.
VIVO' s Days Inventory Range Over the Past 10 Years
Min: 130.86  Med: 178.85 Max: 222.81
Current: 222.81
130.86
222.81
Days Sales Outstanding 45.27
VIVO's Days Sales Outstanding is ranked higher than
73% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 61.18 vs. VIVO: 45.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
VIVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.91  Med: 53.72 Max: 67.24
Current: 45.27
44.91
67.24
Days Payable 39.12
VIVO's Days Payable is ranked lower than
62% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 57.49 vs. VIVO: 39.12 )
Ranked among companies with meaningful Days Payable only.
VIVO' s Days Payable Range Over the Past 10 Years
Min: 25.32  Med: 33.24 Max: 45.39
Current: 39.12
25.32
45.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.58
VIVO's Dividend Yield % is ranked higher than
93% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. VIVO: 5.58 )
Ranked among companies with meaningful Dividend Yield % only.
VIVO' s Dividend Yield % Range Over the Past 10 Years
Min: 1.24  Med: 3.45 Max: 6.32
Current: 5.58
1.24
6.32
Dividend Payout Ratio 1.14
VIVO's Dividend Payout Ratio is ranked lower than
92% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.25 vs. VIVO: 1.14 )
Ranked among companies with meaningful Dividend Payout Ratio only.
VIVO' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.61  Med: 0.95 Max: 1.17
Current: 1.14
0.61
1.17
3-Year Dividend Growth Rate 1.70
VIVO's 3-Year Dividend Growth Rate is ranked lower than
72% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.30 vs. VIVO: 1.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
VIVO' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0.9  Med: 12.8 Max: 37.5
Current: 1.7
0.9
37.5
Forward Dividend Yield % 3.91
VIVO's Forward Dividend Yield % is ranked higher than
87% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.09 vs. VIVO: 3.91 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.95
VIVO's 5-Year Yield-on-Cost % is ranked higher than
92% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. VIVO: 5.95 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
VIVO' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.32  Med: 3.68 Max: 6.74
Current: 5.95
1.32
6.74
3-Year Average Share Buyback Ratio -0.50
VIVO's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. VIVO: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VIVO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.8  Med: -0.7 Max: -0.3
Current: -0.5
-5.8
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 13.08
VIVO's Price-to-Net-Current-Asset-Value is ranked lower than
63% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.22 vs. VIVO: 13.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
VIVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7  Med: 11.3 Max: 65
Current: 13.08
7
65
Price-to-Tangible-Book 7.23
VIVO's Price-to-Tangible-Book is ranked lower than
66% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.72 vs. VIVO: 7.23 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
VIVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.6  Med: 8.84 Max: 13.03
Current: 7.23
3.6
13.03
Price-to-Intrinsic-Value-Projected-FCF 1.25
VIVO's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. VIVO: 1.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
VIVO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.17  Med: 2.44 Max: 4.1
Current: 1.25
1.17
4.1
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.73
VIVO's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
56% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.82 vs. VIVO: 1.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 0.54
VIVO's Price-to-Median-PS-Value is ranked higher than
81% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. VIVO: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
VIVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.12  Med: 0.86 Max: 1.99
Current: 0.54
0.12
1.99
Price-to-Graham-Number 2.44
VIVO's Price-to-Graham-Number is ranked higher than
61% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.91 vs. VIVO: 2.44 )
Ranked among companies with meaningful Price-to-Graham-Number only.
VIVO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.09  Med: 3.18 Max: 5.31
Current: 2.44
2.09
5.31
Earnings Yield (Greenblatt) % 8.63
VIVO's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.78 vs. VIVO: 8.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
VIVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.9  Med: 6 Max: 8.8
Current: 8.63
2.9
8.8
Forward Rate of Return (Yacktman) % 8.79
VIVO's Forward Rate of Return (Yacktman) % is ranked higher than
52% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.41 vs. VIVO: 8.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
VIVO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.5  Med: 10.45 Max: 26.8
Current: 8.79
1.5
26.8

More Statistics

Revenue (TTM) (Mil) $195.7
EPS (TTM) $ 0.70
Beta0.57
Short Percentage of Float10.36%
52-Week Range $10.75 - 21.49
Shares Outstanding (Mil)42.20

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 195 197
EPS ($) 0.75 0.71
EPS without NRI ($) 0.75 0.71
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
9 Cheap High-Yield Stocks Feb 23 2017 
The Four Horsemen: Risk, Uncertainty, Price and Value Mar 19 2015 
Guru-Held Stocks Trading At Historical Low P/B Oct 08 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
13 Stocks Delivering What's Important: Dividend Increases Jan 27 2014 
68 Top Dividend Stocks with Ex-Dividend Date in August 2013 Jul 29 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
15 of the Best Growing Dividend Achievers Jul 30 2012 

More From Other Websites
Meridian (VIVO) to Provide LeadCare Testing System in Africa Mar 08 2017
Magellan Diagnostics (Meridian Bioscience, Inc., NASDAQ: VIVO) Continues Global Development, Signs... Mar 07 2017
Lifshitz & Miller LLP Announces Investigation of Aetna Inc., GenVec, Inc., Ixia, McKesson... Feb 17 2017
MERIDIAN BIOSCIENCE INC Financials Feb 15 2017
MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Feb 09 2017
Bioline Launches New JetSeq(TM) DNA Library Preparation Kits Feb 08 2017
Bioline Launches New JetSeq™ DNA Library Preparation Kits Feb 08 2017
Pawar Law Group Announces Investigation of Securities Claims Against Meridian Bioscience, Inc. -... Feb 07 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving... Feb 03 2017
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Meridian Bioscience,... Feb 03 2017
Meridian Bioscience Announces the Launch of TruQuick(TM) Rapid Tests for Asia Pacific Feb 03 2017
Meridian Bioscience Announces the Launch of TruQuick™ Rapid Tests for Asia Pacific Feb 03 2017
EQUITY ALERT: Rosen Law Firm Continues Investigation of Securities Claims Against Meridian... Feb 03 2017
ETFs with exposure to Meridian Bioscience, Inc. : February 2, 2017 Feb 02 2017
What Makes Meridian Bioscience (VIVO) a Strong Sell? Feb 02 2017
Ex-CEO of TD Ameritrade Sells Shares, Co-Founder of Chipmaker Offloads Shares, Plus Insider Buying... Jan 31 2017
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 26 2017
Meridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q1, 2017 By the Numbers : January 26, 2017 Jan 26 2017
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Meridian Bioscience, Inc.... Jan 25 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Meridian... Jan 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)